FMP
VanEck Pharmaceutical ETF
PPH
NASDAQ
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
85.31 USD
-1.17 (-1.37%)
N/A
Financial Services
Asset Management
NASDAQ
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
0001137360
US92189F6925
92189F692
N/A
NA
US
N/A
Feb 1, 2000
We are unable to load the chart at this time.
We are unable to load the chart at this time.
US92189F6925
NASDAQ
0.56
985.07M
83.74-99.51
218.22k
85.31
US
611.19M
26
88.95
USD
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Zacks Investment Research
Aug 14, 2024
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
ETF Trends
Aug 14, 2024
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
Seeking Alpha
Jul 18, 2024
The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat recession-proof, but high costs and regulatory risks are potential drawbacks.
Zacks Investment Research
Jul 9, 2024
Launched on 12/20/2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Zacks Investment Research
May 9, 2024
The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
ETF Trends
May 7, 2024
Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.
Zacks Investment Research
May 7, 2024
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
ETF Trends
Apr 30, 2024
Weight-loss drugs, including Ozempic, are reshaping consumer habits. Additionally, they are providing some ballast to what's recently been a sluggish healthcare investment thesis.